Shares of Quest Diagnostics and Cutera Upgraded in November
Wall St. Watchdog reveals information about companies for which stock analysts upgraded shares in the Healthcare sector for the week ending November 11th, 2011.
- Quest Diagnostics (NYSE:DGX): RBC Capital Mkts upgraded its rating on this company from Sector Perform to Outperform and changed its price target from $50 to $68 on Nov 7th. The shares recently traded at $57.39, up $0.56, or 0.99% since the analyst’s rating. About the company: Quest Diagnostics Incorporated provides diagnostic testing, information, and services. The Company operates a national network of full-service laboratories, rapid response laboratories, and patient service centers. Quest Diagnostics provides esoteric testing, routine medical testing, drugs of abuse testing, and non-hospital-based anatomicpathology testing. Get the most recent company news and stock data here >>
- Cutera (NASDAQ:CUTR): Maxim Group upgraded its rating on this company from Hold to Buy and changed its price target to $9 on Nov 8th. About the company: Cutera, Inc. develops and manufactures aesthetic laser systems. The Company markets the CoolGlide family of products for removal of unwanted hair and treatment of vascular lesions. Cutera markets the systems to dermatologists, plastic surgeons, and other practitioners worldwide. Get the most recent company news and stock data here >>
(Note: Selected financial data are sourced from Briefing.com via the Wall St. Journal. All data are assumed to be accurate.)
Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>